Compare Stocks: EVOK, LONA, MNOV, and SPRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$11.00 +0.4%	$10.90	$2.28 ▼ $11.00	$18.92M	-0.15	983,927 shs	47,100 shs
LONA Athira Pharma	$7.94 +0.6%	$8.16	$3.52 ▼ $14.21	$74.58M	2.04	49,777 shs	5,134 shs
MNOV MediciNova	$1.44 +1.1%	$1.36	$1.17 ▼ $1.96	$70.63M	0.63	39,216 shs	16,889 shs
SPRO Spero Therapeutics	$1.20 -0.8%	$1.56	$1.08 ▼ $3.08	$69.88M	1.55	618,304 shs	312,274 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	0.00%	0.00%	0.00%	0.00%	+100.36%
LONA Athira Pharma	0.00%	+3.39%	+8.92%	-16.77%	+793,999,900.00%
MNOV MediciNova	0.00%	+3.24%	+7.09%	+5.51%	+7.09%
SPRO Spero Therapeutics	0.00%	-1.64%	0.00%	-57.60%	-39.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$11.00 +0.4%	$10.90	$2.28 ▼ $11.00	$18.92M	-0.15	983,927 shs	47,100 shs
LONA Athira Pharma	$7.94 +0.6%	$8.16	$3.52 ▼ $14.21	$74.58M	2.04	49,777 shs	5,134 shs
MNOV MediciNova	$1.44 +1.1%	$1.36	$1.17 ▼ $1.96	$70.63M	0.63	39,216 shs	16,889 shs
SPRO Spero Therapeutics	$1.20 -0.8%	$1.56	$1.08 ▼ $3.08	$69.88M	1.55	618,304 shs	312,274 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	0.00%	0.00%	0.00%	0.00%	+100.36%
LONA Athira Pharma	0.00%	+3.39%	+8.92%	-16.77%	+793,999,900.00%
MNOV MediciNova	0.00%	+3.24%	+7.09%	+5.51%	+7.09%
SPRO Spero Therapeutics	0.00%	-1.64%	0.00%	-57.60%	-39.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVOK Evoke Pharma	1.50	Reduce	N/A	N/A
LONA Athira Pharma	2.50	Moderate Buy	$17.33	118.30% Upside
MNOV MediciNova	2.67	Moderate Buy	$8.33	480.72% Upside
SPRO Spero Therapeutics	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest EVOK, LONA, MNOV, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	LONA Athira Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/17/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$18.00 ➝ $17.00
8/12/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/11/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVOK Evoke Pharma	$10.25M	1.85	N/A	N/A	$4.74 per share	2.32
LONA Athira Pharma	N/A	N/A	N/A	N/A	$3.58 per share	N/A
MNOV MediciNova	$410K	172.27	N/A	N/A	$0.76 per share	1.89
SPRO Spero Therapeutics	$42.96M	1.63	$0.15 per share	7.89	$0.76 per share	1.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVOK Evoke Pharma	-$5.35M	-$2.07	N/A	N/A	N/A	-36.23%	-101.40%	-31.86%	N/A
LONA Athira Pharma	-$105.61M	-$4.21	N/A	N/A	N/A	N/A	-411.58%	-225.73%	N/A
MNOV MediciNova	-$12M	-$0.21	N/A	N/A	N/A	-1,168.70%	-26.51%	-24.39%	11/12/2026 (Estimated)
SPRO Spero Therapeutics	$8.57M	$0.11	10.91	N/A	N/A	24.90%	16.17%	12.57%	11/12/2026 (Estimated)

Latest EVOK, LONA, MNOV, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LONA Athira Pharma	-$0.60	-$0.80	-$0.20	-$0.80	N/A	N/A
8/13/2026	Q2 2026	MNOV MediciNova	-$0.0633	-$0.05	+$0.0133	-$0.05	$0.08 million	$0.46 million
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	$0.06	5.00%	N/A	54.55%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVOK Evoke Pharma	N/A	1.27	1.22
LONA Athira Pharma	N/A	7.01	7.01
MNOV MediciNova	N/A	8.75	8.75
SPRO Spero Therapeutics	N/A	6.12	6.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVOK Evoke Pharma	N/A
LONA Athira Pharma	57.12%
MNOV MediciNova	9.90%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
EVOK Evoke Pharma	2.29%
LONA Athira Pharma	25.73%
MNOV MediciNova	14.00%
SPRO Spero Therapeutics	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVOK Evoke Pharma	4	1.72 million	1.68 million	Not Optionable
LONA Athira Pharma	40	9.39 million	6.98 million	No Data
MNOV MediciNova	10	49.22 million	42.33 million	Optionable
SPRO Spero Therapeutics	150	58.24 million	56.55 million	Optionable

EVOK, LONA, MNOV, and SPRO Headlines

Recent News About These Companies

Resilient Spero Therapeutics stock prepares up to $300 million shelf as Nasdaq price holds around $1.20

August 29 at 7:24 PM | ad-hoc-news.deA

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO

August 18, 2026 | marketbeat.com

Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

August 13, 2026 | finanznachrichten.de

Spero outlines cash runway into the second half of 2029 following $105M royalty financing

August 13, 2026 | seekingalpha.com

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

Spero Therapeutics Q2 Earnings Call Highlights

August 12, 2026 | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.01 EPS

August 12, 2026 | marketbeat.com

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

August 12, 2026 | globenewswire.com

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 5, 2026 | globenewswire.com

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

August 4, 2026 | globenewswire.com

Spero Therapeutics (SPRO) Expected to Post Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?

August 4, 2026 | marketbeat.com

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

July 27, 2026 | globenewswire.com

Spero Therapeutics inks major CD40L and royalty deals

July 16, 2026 | theglobeandmail.com

Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing

July 14, 2026 | seekingalpha.com

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

July 14, 2026 | reuters.com

Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B

July 14, 2026 | msn.com

Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)

July 14, 2026 | finance.yahoo.com

Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029

July 14, 2026 | quiverquant.comQ

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

July 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, LONA, MNOV, and SPRO Company Descriptions

Evoke Pharma NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Athira Pharma NASDAQ:LONA

$7.94 +0.05 (+0.63%)

As of 08/28/2026 03:16 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

MediciNova NASDAQ:MNOV

$1.44 +0.02 (+1.06%)

As of 08/28/2026 04:00 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Spero Therapeutics NASDAQ:SPRO

$1.20 -0.01 (-0.83%)

As of 08/28/2026 04:00 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVOK, LONA, MNOV, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVOK, LONA, MNOV, and SPRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVOK, LONA, MNOV, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, LONA, MNOV, and SPRO Company Descriptions

Evoke Pharma NASDAQ:EVOK

Athira Pharma NASDAQ:LONA

MediciNova NASDAQ:MNOV

Spero Therapeutics NASDAQ:SPRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVOK, LONA, MNOV, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVOK, LONA, MNOV, and SPRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVOK, LONA, MNOV, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, LONA, MNOV, and SPRO Company Descriptions

Evoke Pharma NASDAQ:EVOK

Athira Pharma NASDAQ:LONA

MediciNova NASDAQ:MNOV

Spero Therapeutics NASDAQ:SPRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools